
Releases
Erasca Faces Securities Class Action Over Misleading Drug Claims
Investors who purchased Erasca, Inc. shares between January 14, 2025, and April 26, 2026, are being urged to join a class action lawsuit. The litigation alleges the company misled the market regarding the development and patent risks associated with its ERAS-0015 therapeutic candidate.






















